Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
| Revenue (TTM) | $37.22B |
| Gross Profit (TTM) | $26.59B |
| EBITDA | $16.92B |
| Operating Margin | 33.80% |
| Return on Equity | 101.30% |
| Return on Assets | 8.35% |
| Revenue/Share (TTM) | $69.12 |
| Book Value | $17.03 |
| Price-to-Book | 22.10 |
| Price-to-Sales (TTM) | 5.70 |
| EV/Revenue | 6.67 |
| EV/EBITDA | 14.90 |
| Quarterly Earnings Growth (YoY) | 4.40% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $539.71M |
| Float | $538.22M |
| % Insiders | 0.22% |
| % Institutions | 87.14% |
Volatility is currently expanding
THOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen said on Friday it submitted new evidence to the FDA on July 23 as it seeks a hearing to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market.
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMGN and any ticker you trade — then tracks every position and per-strategy win rate.
